Rodrigo Sanchez Roger

El efecto sumidero en la terapia con Lu-177–PSMA significa que en pacientes con alta carga tumoral, los tumores “captan” la mayor parte del radioligando, reduciendo la captación en órganos normales (glándulas salivales, riñones). Más tumor = menos exposición de tejidos sanos. The sink effect in Lu-177–PSMA therapy means that in patients with high tumor burden, tumors “trap” most of the radioligand, reducing uptake in normal organs (salivary glands, kidneys). More tumor = less normal tissue exposure.

Is this the end of cisplatin in MIBC? With the results from NIAGARA, KEYNOTE-B15/EV-304, and KEYNOTE-905/EV-303, along with the emergence of ctDNA in IMvigor011, it is becoming increasingly difficult to defend it as the sole backbone of perioperative treatment. Are we truly witnessing a paradigm shift, or is it still too early to move on? #BladderCancer #trendingtopicsinGu @Uromigos @Uro_Oncologist @tompowles1 @docjavip @karima_oualla

A 240 pateint single arm trial exploring 9 cycles of EVP without planned surgery in MIBC. This will answer the key questions ‘What happens if we don’t do cystectomy in those with clinical complete response after initial EVP’.It assesses cCR rates and bladder intact EFS. It will clarify ‘EVP 1st ask questions later’ #GUtrendingTopics @OncoAlert

@aaoncoclinica 🎯Excelente discusión de #ctDNA #cavejiga gracias #AAOC @Iván Macharashvilli

POST GIGU - Bariloche 2026 MÓDULO UROTELIO | Moderadora: Dra. Andrea Marchioni. Dr. Iván Macharashvilli - Dr. Rodrigo Sánchez.

#PosGIGU2026 iniciando dias 1, la urroncologoa de Argentina en #Bariloche

#EAU26 @tompowles1 blunt take on the evolving UC landscape: EVP first. Questions later! 🔹 Platinum chemo → no clear role in 1L 🔹 Focus now on managing EV+P toxicity 🔹 Other ADC + IO combos are emerging (DV+Tori) 🔹 In perioperative EV+P relapse → platinum may come back The paradigm is shifting fast. @uroweb @UroToday

#EAU26 ctDNA to guide adjuvant therapy after cystectomy? •Conventional risk stratification may not be enough. ctDNA positivity strongly predicts recurrence after RC • Christensen et al: ctDNA+ → markedly higher relapse risk • IMvigor010: benefit from adjuvant IO mainly in ctDNA+ pts ✅IMvigor011: ctDNA-guided atezolizumab improved DFS in ctDNA+ pts @JBjerggaard: Yes, we are ready to guide adjuvant therapy with ctDNA! @uroweb @UroToday

Updates of IO in NMIBC tríals at #eue2026

Bladder stones ≠ mandatory BPH surgery: Personalizing males treatment. Take a look at our multicenter study. onlinelibrary.wiley.com/doi/10.1002/pr… @MantuGuptaMD @mario_sofer @Mendelson_Tomer @lrahmanimd @MountsinaiUro @UrologyTLVMC

⚡️ Variant histology in MIBC isn’t a footnote—it can drive staging, relapse risk, and response to systemic therapy. This review highlights a persistent problem: subtype misclassification (and why expert/central pathology matters), plus the push for trials that include variant subtypes rather than excluding them. #BladderCancer #MIBC #UroOnc dailynews.ascopubs.org/do/advancing-p…

¿Podría la anhidrasa carbónica IX (CAIX) convertirse para el cáncer renal en lo que el PSMA representa para el cáncer de próstata, tanto en diagnóstico como en tratamiento? @DrMHofman

IMVIGOR011: ctDNA guided adjuvant atezolizumab in MIBC shows a ctDNA risk adapted approach identified high risk patients who benefit from ICI therapy, sparing persistently ctDNA-ves (at much lower risk) toxicity. Here #GU26 we show ctDNA+ves have dynamic MTM levels (a bit like PSA). ⬆️ MTM levels have poor prognosis. MTM reduction with atezo = better outcomes. But low MTM at baseline levels still do poorly (compared to persistently negatives) meaning all ctDNA +ves are at risk. These data suggests MTM levels adds useful prognostic information beyond the binary ctDNA +ve vs ctDNA -ve status. @OncoAlert

The INDIBLADE Trial (n=50): Neoadjuvant Ipi/nivo then Chemoradiotherapy in muscle invasive bladder cancer shows 2 yr Bladder-Intact EFS of 78% & 2 yr OS of 96%. #GU26 @MichvdHeijden . ⬆️⬆️ than previous chemo/rad trials. Only 39% ctDNA+ve at baseline suggests a lower risk population compared to NIAGARA (57%). CtDNA clearance with IPI/Nivo=76% is ⬆️ (gem/cis/durva=70%). IPI/nivo/TMT looks good. VOLGA is the last chance to answer the CTLA4 question. Outcome in MIBC is strongly influenced by the presence on MRD at baseline (2 yr DFS for IPI/nivo surgery was ~70%).

There has been a lot of data on ctDNA in bladder cancer #GU26, but less on tumor DNA in the urine (utDNA). In this informed utDNA analysis from NIAGARA we show extensive utDNA positivity at baseline & clearance with neoadjuvant therapy. There is also a better correlation with utDNA and pCR than with ctDNA. This dual approach helps determine the origin of thr MRD (local vs systemic). False positive rates at CR need addressing. Clearance could be a marker of local therapy activity #GU26 @MichvdHeijden @MattGalsky

🎯Un nuevo desafío para la #Urooncologia #Argentina referentes de todo el país invitados a participar y votar sobre #CaProstata @APCCC_Lugano @oncourologiaarg @OncoAlert

This is how we finally start harnessing the untapped for decades power of *prognostic* modeling (not “predictive”) for biomarker development. Onwards! 🔬@ChadTangMD @VincentWenxinXu @AlexSherryMD @OncHahn @AmandaNizamMD @KidneyCancer @ebludmir @PGrivasMDPhD

🎯Presente la unidad GU #HospitalMilitarCentral 👏👏

@Larvol @ASCO Congratulations team, great job at this #AscoGu2026

Top Cancer Institutes on 𝕏 during @ASCO GU 2026, based on oncologists' posts and views. Explore more insights and data from #GU26: bit.ly/3YGGH2w #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #GUCancer #GenitourinaryCancer #GUCSM #ASCOGU2026 | @aiims_newdelhi | @DanaFarber | @UIHealth | @fortis_hospital | @NHSBartsHealth | @AnkaraUni | @UHhospitals | @theNCI | @HCIoncopharm | @ClevelandClinic | @incmnszmx | @InstitutoRoffo | @CedarsSinai | @GACancerCenter | @UTSWMedCenter | @HopkinsMedicine | @memorial_group | @IAF_Fleming | @cityofhope | @PennStHershey | @HUCA_Asturias | @dukecancer | @MassGeneralNews | @DrRishabhOnco | @DrChoueiri | @DrKarineTawagi | @SuyogCancer | @tompowles1 | @DrYukselUrun | @DrSpratticus | @neerajaiims | @BourlonMaite | @RodRogSan | @nataliagandur | @yekeduz_emre | @Dr_RaviMadan | @shilpaonc